54 results about "FAMILY ENTEROBACTERIACEAE" patented technology

An L-amino acid is produced by culturing a microorganism belonging to the family Enterobacteriaceae having an L-amino acid-producing ability and modified so that glycerol dehydrogenase and dihydroxyacetone kinase activities are increased, in a medium containing glycerol as a carbon source to produce and accumulate an L-amino acid in the medium or cells, and collecting the L-amino acid from the medium or the cells.

The present invention provides a method for producing L-isoleucine by fermentation using a bacterium belonging to the family Enterobacteriaceae which has been modified to overexpress the cycA gene. The method also allows reducing the amount of byproduct amino acids that are produced during fementative production of L-isoleucine using Enterobacteriaceae bacterium having an L-isoleucine-producing ability.

The invention relates to the field of microorganisms, and in particular relates to a bacterium for fermenting L-tryptophan from mixed saccharum and a fermentation method thereof. The Enterobacteriaceae bacterium for producing L-tryptophan can have the capability of simultaneously utilizing hexose and pentose to produce the L-tryptophan because of containing the coding gene of a cAMP receptor protein mutant. The cAMP receptor protein mutant is obtained through mutating one or a plurality of amino acid loci of the cAMP receptor protein. The bacterium provided by the invention consumes glucose and xylose in a culture medium containing the glucose and the xylose at the same time, and the yield and conversion rate of the L-tryptophan are increased.

A method for producing an L-amino acid includes culturing a bacterium which belongs to the family Enterobacteriaceae and has an L-amino acid-producing ability in a medium containing a carbon source selected from a fatty acid and an alcohol, and collecting the L-amino acid from the medium. A bacterium which has been subjected to a modification including at least one of enhancement of oxyS gene expression, enhancement of fixABC gene expression, and combination thereof, is used as the bacterium, or a substance that reduces intracellular hydrogen peroxide concentration of the bacterium is added to the medium.

The invention provides a novel method for producing L-cysteine. The method adopts the gene having the ingesting activity of L-cysteine in the bacterium belonging to the family Enterobacteriaceae. The present invention provides a bacterium belonging to the family Enterobacteriaceae, which is able to produce L-cysteine, and has been modified to decrease activity of the YdjN protein, or the activities of the YdjN and the FliY protein. This bacterium is cultured in a medium, and L-cysteine, L-cystine, a derivative or precursor thereof, or a mixture of these can be collected from the medium.

The present invention provides a bacterium belonging to the family Enterobacteriaceae, which is able to produce L-cysteine and has been modified to increase the activity of the protein encoded by the dsbA gene. This bacterium is cultured in a medium, and L-cysteine, L-cystine, a derivative or precursor thereof or a mixture thereof can be collected from the medium.

An organic acid is produced by allowing a bacterium belonging to the family Enterobacteriaceae, which has an ability to produce an organic acid and has been modified so that the phosphoenolpyruvate carboxykinase activity is enhanced, and the glucose phosphotransferase activity is decreased, which is selected from Escherichia, Enterobacter, Pantoea, Erwinia, Klebsiella and Raoultella bacteria, or a product obtained by processing the bacterium, to act on an organic raw material in a reaction mixture containing carbonate ions, bicarbonate ions, or carbon dioxide gas to produce the organic acid.

A method for increasing gastric tract acid (GTA) production in a mammalian subject. The method comprises administering a therapeutically-effective amount of a composition comprising at least one liveor attenuated culture of a microbial species selected from the genus Blautia, species Faecalibacterium prausnitzii, genus Bacteroides, family Ruminococcaceae, family Lachnospiraceae, genus Coprococcus, genus Roseburia, genus Oscillospira, species Ruminococcus bromii, genus Ruminococcus, family Costridiaceae, species Dorea formicigenerans, species Bacteroides uniformis, genus Dorea, genus Streptococcus, order Clostridiales, genus Anaerostipes, genus Dialister, species Bifidobacterium adolescentis, family Coriobacteriaceae, genus Faecalibacterium, genus Sutterella, species Bacteroides ovatus, genus Parabacteroides, genus Ruminococcus, species Bacteroides faecis, species Eubacterium biforme, genus Phascolartobacterium, and family Enterobacteriaceae; or a prebiotic composition which increasesgrowth and / or viability of said microbial species in the gut. Administering the composition increases the synthesis of at least one GTA dicarboxylic fatty acid metabolite in said subject. Also described are method for determining gastrointestinal inflammation status and kits for detecting and treating a gastric tract acid (GTA) insufficiency.